TerminatedPhase 2NCT03155932

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Studying Primary biliary cholangitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Arena Pharmaceuticals
Principal Investigator: Arena CT.gov Administrator
Arena Pharmaceuticals
Intervention: APD334(drug)
Enrollment: 2 target
Eligibility: 18-80 years · All sexes
Timeline: 2017 – 2019

Study locations (9)

Gastroenterology and Hepatology, UC Davis Medical Center, Sacramento, California, United States
Baylor College of Medicine, Houston, Texas, United States
Texas Liver Institute, San Antonio, Texas, United States
Swedish Medical Center, Seattle, Washington, United States
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Sunshine Coast University Hospital, Birtinya, Queensland, Australia
Alfred Health, Melbourne, Victoria, Australia
Auckland City Hospital, Grafton, Auckland, New Zealand
Christchurch Clinical Studies Trust, Christchurch, New Zealand

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03155932 on ClinicalTrials.gov

Other trials for Primary biliary cholangitis

Additional recruiting or active studies for the same condition.

See all trials for Primary biliary cholangitis →

← Back to all trials